Arena Pharma (Nasdaq: ARNA) trading halted, as expected, as an FDA advisory panel is set to review its lorcaserin weight-loss ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE